Tarsier Pharma Files for NYSE IPO, Aims to Raise $50 Million

Tarsier Pharma Ltd. has filed for an initial public offering on the New York Stock Exchange, seeking to raise approximately $50 million. The company announced its plans to list its ordinary shares under the proposed ticker symbol TARX.

Offering Details

According to the company's press release, the IPO consists of 5,555,555 ordinary shares. The anticipated price is between $8.00 and $10.00 per share.

• At the midpoint of the proposed range, $9.00 per share, the offering would generate gross proceeds of approximately $50 million before underwriting discounts and commissions.
• Each ordinary share has a par value of NIS 0.001.
• Konik Capital Partners is acting as the sole underwriter for the deal.

Ad

Market Context

This filing marks Tarsier Pharma's first move into the public markets, as no prior public market for its shares has existed. The capital raised from the IPO is typically used by companies to fund research and development, scale operations, or for general corporate purposes.

For investors, the listing will provide the first opportunity to trade Tarsier Pharma's stock on a major public exchange. As is common with newly listed equities, the stock could experience significant volatility in its initial trading sessions as the market establishes a valuation for the company.